Edition:
India

Anthem Inc (ANTM.N)

ANTM.N on New York Stock Exchange

286.33USD
16 Nov 2018
Change (% chg)

$2.19 (+0.77%)
Prev Close
$284.14
Open
$284.15
Day's High
$288.94
Day's Low
$284.00
Volume
360,207
Avg. Vol
321,375
52-wk High
$290.77
52-wk Low
$215.58

Select another date:

Wed, Oct 31 2018

UPDATE 3-Anthem predicts better 2019 than Wall Street forecast, shares rise

Oct 31 Anthem Inc on Wednesday said its own expectations for 2019 earnings are ahead of current Wall Street estimates and the health insurer also raised its 2018 profit forecast, and its shares rose as much as 5 percent.

Takeda hikes annual profit forecast by a third after second-quarter profit jump

TOKYO Japan's Takeda Pharmaceutical Co Ltd on Wednesday boosted its annual operating profit outlook by a third after second-quarter earnings surged on strong global sales of its drugs for bowel disease and multiple myeloma.

CORRECTED-UPDATE 1-Anthem quarterly profit beats estimates, raises 2018 forecast

Oct 31 Anthem Inc reported quarterly profit that topped analysts' estimates on Wednesday on lower medical costs and the No.2 U.S. health insurer raised its full-year adjusted earnings forecast.

UPDATE 2-Takeda hikes annual profit forecast by a third after Q2 profit jump

* Boosted by strong sales of bowel disease, multiple myeloma drugs (Adds executive comments from news conference)

Anthem reports 28.5 pct rise in quarterly profit

Oct 31 Anthem Inc reported a 28.5 percent rise in quarterly profit on Wednesday, as the U.S. health insurer reined in medical costs.

Takeda's raises full-year outlook after Q2 profit rise

TOKYO, Oct 31 Takeda Pharmaceutical Co Ltd on Wednesday raised its annual operating profit outlook to 268.9 billion yen.

Takeda proposes sale of Shire drug to gain European approval

Takeda Pharmaceutical Co Ltd has proposed to European regulators it could sell a Shire treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies' merger.

Takeda proposes sale of Shire drug to gain European approval

Oct 29 Takeda Pharmaceutical Co Ltd has proposed to European regulators it could sell a Shire treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies' merger.

Takeda gets Japanese approval for $62 billion Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker. The deal, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from regulators in the United States, Brazil and China.

Takeda gets Japanese approval for $62 billion Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc , bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

Select another date: